INmune Bio Inc Dossier - Source-backed chat

INmune Bio Inc

INMBNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.91

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.93Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $53.6M

Enterprise Value $43.8M

Shares Outstanding 28.5M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

INmune Bio is transitioning from a mid-stage clinical biotech into a late-stage, registration-directed organization. The investment thesis is anchored by two high-value clinical assets: CORDStrom™ (an off-the-shelf cell therapy for Recessive Dystrophic Epidermolysis Bullosa, or RDEB) and XPro1595 (a selective soluble TNF inhibitor for early Alzheimer's Disease). CORDStrom™ is on the cusp of regulatory submissions in the UK (early Q3 2026) and the US (Q4 2026), targeting a potential $1.4 billion addressable market with high reimbursement potential (~$700,000/patient). Meanwhile, XPro1595 has achieved FDA Fast Track designation and regulatory alignment on an integrated Phase 2b/3 registrational pathway. While the company's cash runway extends only into Q1 2027, positive clinical data and imminent regulatory milestones offer significant near-term upside, provided the company secures strategic partnerships or non-dilutive funding.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$7.00

High · most bullish analyst$9.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.5020%

CORDStrom™ regulatory submissions face unexpected delays or clinical hold requests from the MHRA or FDA, pushing commercialization timelines past 2027. Additionally, the company fails to secure a strategic partner for XPro1595, forcing highly dilutive equity financing to extend its cash runway beyond Q1 2027, severely depressing the stock price.

Base CaseCentral scenario

$7.0050%

Matches the consensus mean

INmune Bio successfully submits the CORDStrom™ MAA to the UK MHRA in early Q3 2026 and the BLA to the US FDA in Q4 2026. The company manages its cash burn efficiently to sustain operations into early 2027 while actively negotiating strategic partnerships for XPro1595. Stock price recovers toward consensus analyst targets as regulatory milestones are met.

Bull CaseUpside scenario

$9.0030%

CORDStrom™ receives rapid approval from the UK MHRA and US FDA, securing a Priority Review Voucher (PRV) worth ~$100M+ and capturing a significant share of the $1.4B RDEB market. Simultaneously, INmune Bio secures a major pharmaceutical partnership to fully fund the Phase 2b/3 registrational trial for XPro1595 in early Alzheimer's Disease, eliminating near-term dilution concerns and validating its precision-medicine, biomarker-enriched approach.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

CORDStrom™ is positioned as potentially the first systemic disease-modifying therapy for RDEB, addressing a severe unmet need with a potential $1.4B addressable market.
XPro1595 has received FDA Fast Track designation and achieved regulatory alignment on a de-risked, biomarker-enriched Phase 2b/3 registrational pathway for early Alzheimer's Disease.
Disciplined cost management has successfully narrowed quarterly net losses (down 44.3% YoY in Q1 2026) and optimized R&D spend.

Key Investment Risks

Limited cash runway ($21.4M as of March 31, 2026) only funds operations through Q1 2027, presenting near-term dilution or financing risks.
The company is dependent on securing strategic partnerships to advance XPro1595 into late-stage trials, as it does not plan to fund development independently.
High regulatory and operational risks associated with pre-commercial biotech firms, including potential trial enrollment delays or regulatory pushback.

Thesis Invalidation Triggers

Rejection or significant delay of the CORDStrom™ MAA submission by the UK MHRA in Q3 2026.
Failure to secure a strategic partner or licensing deal for XPro1595 by early 2027, leading to a halt in the Alzheimer's program.
Severe cash depletion below $10 million without a clear non-dilutive funding source or partnership agreement.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.